Stock Worth Mentioning Today: What Next for HTG Molecular Diagnostics Inc Stock After Reaching 52 Week Low?

Stock Worth Mentioning Today: What Next for HTG Molecular Diagnostics Inc Stock After Reaching 52 Week Low?

The stock of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) hit a new 52-week low and has $1.85 target or 10.00% below today’s $2.05 share price. The 7 months bearish chart indicates high risk for the $14.39 million company. The 1-year low was reported on Nov, 1 by Barchart.com. If the $1.85 price target is reached, the company will be worth $1.44 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 30,043 shares traded hands. HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has declined 28.33% since March 30, 2016 and is downtrending. It has underperformed by 31.35% the S&P500.

Analysts await HTG Molecular Diagnostics Inc (NASDAQ:HTGM) to report earnings on November, 10.

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) Ratings Coverage

Out of 2 analysts covering HTG Molecular Diagnostics (NASDAQ:HTGM), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. HTG Molecular Diagnostics has been the topic of 3 analyst reports since August 24, 2015 according to StockzIntelligence Inc. The rating was maintained by Canaccord Genuity on Tuesday, November 24 with “Buy”. The firm has “Buy” rating by Canaccord Genuity given on Monday, August 24. The stock of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has “Buy” rating given on Monday, August 22 by Rodman & Renshaw.

According to Zacks Investment Research, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona.”

More notable recent HTG Molecular Diagnostics Inc (NASDAQ:HTGM) news were published by: Quotes.Wsj.com which released: “News HTG Molecular Diagnostics Inc.HTGM” on May 01, 2015, also Globenewswire.com with their article: “Don Hardison Joins the Board of Directors for HTG Molecular Diagnostics” published on May 03, 2016, Streetinsider.com published: “HTG Molecular Diagnostics (HTGM), Merck KGaA Enter Board Companion Diagnostics …” on October 11, 2016. More interesting news about HTG Molecular Diagnostics Inc (NASDAQ:HTGM) were released by: Seekingalpha.com and their article: “HTG Molecular Diagnostics’ (HTGM) CEO TJ Johnson on Q1 2016 Results – Earnings …” published on May 13, 2016 as well as Globenewswire.com‘s news article titled: “James (Jim) LaFrance Joins the Board of Directors of HTG Molecular Diagnostics” with publication date: December 02, 2015.

HTGM Company Profile

HTG Molecular Diagnostics, Inc., incorporated on December 14, 2000, is a commercial-stage firm that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company’s HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company’s HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment